Protagonist Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview

Protagonist Therapeutics

02/11/2024 04:08

* Protagonist Therapeutics Inc  PTGX.OQ   PTGX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
November 4 (estimated) for the period ending September 30 2024
    * The Newark California California-based  company is
expected to
report revenue of $1.667 million, according to the mean estimate
from 6 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Protagonist Therapeutics
Inc
is for a loss of 62 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $51.50​, above​ its last closing price
of $46.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.57       -0.60      -0.50     Beat    16.9
 Jan. 1 0001   0.53        1.19       3.26      Beat    173.1
 Dec. 31 2023  0.03        -0.03      0.44      Beat    1,425.
                                                        3​
 Jan. 1 0001   -0.70       -0.69      -0.58     Beat    16.4
 ​​Jan.        -0.65       -0.65      -0.68     Missed  -5
 1 0001                                                 
 Mar. 31 2023  -0.77       -0.73      -0.67     Beat    7.8​
 Dec. 31 2022  -0.52       -0.64      -0.69     Missed  -8.1
 Sep. 30 2022  -0.86       -0.87      -0.64     Beat    26.3
 This summary was machine generated November 2 at 04:07 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)